Archana Verma, MD
Gastroenterology · Clive, IANPI 1821046087
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,237 of the $6,341 with a category attached, or 82.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,032 and has fallen 66.9% since, to $672 in 2025. Among gastroenterology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 282 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boston Scientific$1K
- Johnson & Johnson$757
- Pfizer$473
- Takeda Pharmaceuticals U.S.A., Inc.$272
- Olympus Corporation Of The Americas$219
- plus $2K from 28 others
What the payments were for
- Travel & lodging$1,10417%
- Food & beverage$5,23783%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,446 |
| Boston Scientific | 18 | $1,361 |
| Johnson & Johnson | 50 | $757 |
| Pfizer | 33 | $473 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $272 |
| Olympus Corporation Of The Americas | 3 | $219 |
| Bristol Myers Squibb | 15 | $200 |
| Merit Medical Systems Inc | 1 | $135 |
| ERBE USA Inc | 1 | $128 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Apollo Endosurgery US Inc | 2 | $119 |
| E.r. Squibb & Sons, L.L.C. | 1 | $115 |
| Medtronic | 2 | $112 |
| Braintree Laboratories, Inc. | 6 | $97 |
| Phathom Pharmaceuticals, Inc. | 6 | $97 |
| Lumendi LLC | 1 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $87 |
| UCB, Inc. | 4 | $71 |
| Amgen | 4 | $67 |
| Merck | 3 | $43 |
| Sanofi | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 2 | $39 |
| Ardelyx, Inc. | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $34 |
| Endogastric Solutions, Inc | 1 | $32 |
| Covidien LP | 1 | $22 |
| Boehringer Ingelheim | 1 | $20 |
| QOL Medical, LLC | 1 | $19 |
| Shire North American Group Inc | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Fresenius Kabi USA, LLC | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$255
- Olympus EMR & ESD Devices$156
- Olympus EndoTherapy Accessories$156
- Olympus GI Accessories$156
- Olympus Hemostasis Devices$156
- EXALT Model D$141
- ESOPHYX$135
- Tremfya$132
- Skyrizi$130
- VIO3$128
- Rinvoq$125
- ZEPOSIA$115
How this compares
$6,341 in reported general payments places this provider in the 90th percentile of 113 gastroenterology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 30 | $822,498 |
| Skyrizi On-BodyRisankizumab-Rzaa | 12 | $270,638 |
| Humira(Cf) PenAdalimumab | 21 | $203,219 |
| Humira(Cf)Adalimumab | 13 | $186,462 |
| CreonLipase/Protease/Amylase | 37 | $140,526 |
| RinvoqUpadacitinib | 11 | $127,798 |
| XifaxanRifaximin | 35 | $71,072 |
| LinzessLinaclotide | 44 | $49,450 |
| VemlidyTenofovir Alafenamide | 14 | $20,160 |
| Mesalamine | 30 | $12,200 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 182 | $11,489 |
| Dexlansoprazole DrDexlansoprazole | 21 | $7,184 |
| Budesonide DrBudesonide | 46 | $6,985 |
| Sucralfate | 96 | $6,768 |
| MovantikNaloxegol Oxalate | 14 | $4,616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $757 | $822,49830 claims |
| AbbVieHumira(Cf), Creon, Rinvoq, Linzess | $1,446 | $504,237105 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $87 | $71,07235 claims |
| Fresenius Kabi USA, LLCSodium Chloride, Magnesium Sulfate | $13 | $3,30088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 gastroenterology providers in Iowa.
Other gastroenterology in Clive
- Nagendra MyneniClive$66K
- Bernard LemanClive$12K
- Christopher MulderClive$6K
- Benjamin PottebaumClive$6K
- Amol AgarwalClive$6K
- Tercio LopesClive$5K
- Ravi VemulapalliClive$4K
- Thomas MartinClive$2K
- Rajalakshmi IyerClive$2K
- Jeffrey BrannenClive$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.